A Multi-center, Open-label, Extension Study to Evaluate the Efficacy and Safety of Teprotumumab N01 (IBI311) in Participants with Thyroid Eye Disease

Sycume (teprotumumab N01) - Innovent Biologics

Tepezza (teprotumumab-trbw) - Roche, Amgen

ATI-50001 - Aclaris, Rigel Pharmaceuticals

Huifang ZHOU, MD, PhD; Yihua XU, MD; Xianqun FAN, MD, PhD; Shujie LU, MD; Jing SUN, MD, PhD; Junjie DENG, MD; Haiyang ZHANG, MD; Yinwei LI, MD, PhD

Apr 6, 2026